CoChat
Sign Up
Cited by 80Thyroid Cancer Diagnosis and TreatmentThyroid and Parathyroid SurgeryHead and Neck Cancer Studies

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Anaplastic Thyroid Cancer

Maniakas, Anastasios, Zafereo, Mark, Cabanillas, Maria E.·2022·Endocrinology and Metabolism Clinics of North America
DOI 10.1016/j.ecl.2021.11.020
Open this paper in CoChat — free account

Abstract

Anaplastic thyroid cancer (ATC) remains one of the most aggressive and deadliest malignancies. Traditionally, treatment consisted of cytotoxic chemotherapy and radiation therapy, with or without surgery, although a large proportion of patients were often directed toward palliative/hospice care. In the past decade, significant advances have been made through the advent of targeted therapies and immunotherapy. For patients with targetable disease and considerable treatment response, surgery and other multidisciplinary adjuvant therapies can now be considered. Overall, the era of untreatable ATC is progressively being replaced by highly personalized multidisciplinary therapies, actively shifting the treatment pendulum of this disease.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ecl.2021.11.020

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 4 references

Research works printed but not linked: 56

  1. Lin, 2019, The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis, Am J translational Res, 11, 5888
  2. Maniakas, 2020, Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019, JAMA Oncol, 6, 1397, 10.1001/jamaoncol.2020.3362 · DOI
  3. Are, 2006, Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches, Ann Surg Oncol, 13, 453, 10.1245/ASO.2006.05.042 · DOI
  4. Smallridge, 2009, Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies, Endocr-related cancer, 16, 17, 10.1677/ERC-08-0154 · DOI
  5. Smallridge, 2012, American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer, Thyroid, 22, 1104, 10.1089/thy.2012.0302 · DOI
  6. Tuttle, 2017, Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why?, Thyroid, 27, 751, 10.1089/thy.2017.0102 · DOI
  7. Pozdeyev, 2018, Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers, Clin Cancer Res : official J Am Assoc Cancer Res, 24, 3059, 10.1158/1078-0432.CCR-18-0373 · DOI
  8. Wang, 2019, Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma, Thyroid, 29, 1036, 10.1089/thy.2019.0133 · DOI · Paper page
  9. Xu, 2020, Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 Cases, Thyroid, 30, 1505, 10.1089/thy.2020.0086 · DOI
  10. Oishi, 2017, Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation, Mod Pathol, 30, 1527, 10.1038/modpathol.2017.75 · DOI
  11. Bible, 2021, 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer, Thyroid, 31, 337, 10.1089/thy.2020.0944 · DOI
  12. Janz, 2019, Is the incidence of anaplastic thyroid cancer increasing: A population based epidemiology study, World J Otorhinolaryngol - Head Neck Surg, 5, 34, 10.1016/j.wjorl.2018.05.006 · DOI
  13. Iyer, 2018, Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma, JCO Precision Oncol, 1
  14. Cabanillas, 2017, Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer, Head & neck, 39, 1291, 10.1002/hed.24784 · DOI
  15. Subbiah, 2018, Dabrafenib and trametinib treatment in patients with locally advanced or metastatic braf v600-mutant anaplastic thyroid cancer, J Clin Oncol, 36, 7, 10.1200/JCO.2017.73.6785 · DOI
  16. Henderson, 2021, A high-throughput approach to identify effective systemic agents for the treatment of anaplastic thyroid carcinoma, J Clin Endocrinol Metab, 106, 2962, 10.1210/clinem/dgab424 · DOI
  17. Maniakas, 2021, Novel anaplastic thyroid cancer PDXs and cell lines: Expanding preclinical models of genetic diversity, J Clin Endocrinol Metab, 106, e4652, 10.1210/clinem/dgab453 · DOI
  18. Qin, 2021, Clinical utility of circulating cell-free dna mutations in anaplastic thyroid carcinoma, Thyroid, 31, 1235, 10.1089/thy.2020.0296 · DOI
  19. Corcoran, 2018, Application of Cell-free DNA Analysis to Cancer Treatment, New Engl J Med, 379, 1754, 10.1056/NEJMra1706174 · DOI
  20. Sandulache, 2017, Real-time genomic characterization utilizing circulating cell-free dna in patients with anaplastic thyroid carcinoma, Thyroid, 27, 81, 10.1089/thy.2016.0076 · DOI
  21. Wang, 2018, An acquired vulnerability of drug-resistant melanoma with therapeutic potential, Cell, 173, 1413, 10.1016/j.cell.2018.04.012 · DOI
  22. Facchinetti, 2020, 132, 211
  23. Villanueva, 2010, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K, Cancer Cell, 18, 683, 10.1016/j.ccr.2010.11.023 · DOI
  24. Van Allen, 2014, The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma, Cancer Discov, 4, 94, 10.1158/2159-8290.CD-13-0617 · DOI
  25. Danysh, 2016, Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model, Oncotarget, 7, 30907, 10.18632/oncotarget.9023 · DOI
  26. Owen, 2019, KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer, J Natl Compr Cancer Netw, 17, 409, 10.6004/jnccn.2019.7292 · DOI
  27. Cabanillas, 2020, Acquired Secondary RAS Mutation in BRAF(V600E)-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors, Thyroid, 30, 1288, 10.1089/thy.2019.0514 · DOI
  28. Kimura, 2003, High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma, Cancer Res, 63, 1454
  29. Iyer, 2018, Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma, J Immunother Cancer, 6, 68, 10.1186/s40425-018-0378-y · DOI
  30. Cabanillas, 2019, OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility, J Endocr Soc, 3
  31. Chen, 2018, Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy, Mol Cancer Ther, 17, 1575, 10.1158/1535-7163.MCT-17-0871 · DOI
  32. Dadu, 2015, Targeting immune system in anaplastic thyroid cancer (ATC): a potential treatment approach, Thyroid, Supplement 1, 749
  33. Adam, 2021, FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale, Front Endocrinol, 12, 712107, 10.3389/fendo.2021.712107 · DOI
  34. Capdevila, 2020, PD-1 Blockade in Anaplastic Thyroid Carcinoma, J Clin Oncol, 38, 2620, 10.1200/JCO.19.02727 · DOI
  35. Brauner, 2016, Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer, Oncotarget, 7, 17194, 10.18632/oncotarget.7839 · DOI
  36. Zheng, 2021, Response to immunotherapy in a patient with anaplastic thyroid cancer: A case report, Medicine, 100, e26138, 10.1097/MD.0000000000026138 · DOI
  37. Nabhan, 2021, Pembrolizumab in a Patient with Treatment-Naïve Unresectable BRAF-Mutation Negative Anaplastic Thyroid Cancer, Case Rep Endocrinol, 2021, 5521649
  38. Yang, 2021, Anaplastic Thyroid Cancer Successfully Treated With Radiation and Immunotherapy: A Case Report, AACE Clin case Rep, 7, 299
  39. Lorch, 2020, A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC), J Clin Oncol, 38, 6513, 10.1200/JCO.2020.38.15_suppl.6513 · DOI
  40. Gunda, 2019, Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer, Int J Cancer, 144, 2266, 10.1002/ijc.32041 · DOI
  41. Dierks, 2021, Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma, Thyroid, 31, 1076, 10.1089/thy.2020.0322 · DOI
  42. Dierks, 2020, Ann Oncol, 31, S1085, 10.1016/j.annonc.2020.08.1403 · DOI
  43. Dierks, 2021, Lenvatinib/Pembrolizumab in Metastasized Anaplastic Thyroid Carcinoma (ATC): Interim results of the ATLEP Trial, Thyroid, 31
  44. Cabanillas, 2019, Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond, Endocr Rev, 40, 1573, 10.1210/er.2019-00007 · DOI
  45. Kelly, 2014, Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer, Proc Natl Acad Sci USA, 111, 4233, 10.1073/pnas.1321937111 · DOI
  46. Santoro, 2020, RET Gene Fusions in Malignancies of the Thyroid and Other Tissues, Genes, 11, 10.3390/genes11040424 · DOI
  47. Cabanillas, 2020, 1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer, Ann Oncol, 31, S1086, 10.1016/j.annonc.2020.08.1404 · DOI
  48. Waguespack, 2021, Long-term Efficacy and Safety of Larotrectinib in Patients with Advanced TRK Fusion-positive Thyroid Carcinoma, Thyroid, 31, A
  49. Wirth, 2020, Efficacy of Selpercatinib in RET-Altered Thyroid Cancers, New Engl J Med, 383, 825, 10.1056/NEJMoa2005651 · DOI
  50. Subbiah, 2021, Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study, Lancet Diabetes Endocrinol, 9, 491, 10.1016/S2213-8587(21)00120-0 · DOI
  51. Isham, 2013, Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer, Sci translational Med, 5, 166ra3, 10.1126/scitranslmed.3004358 · DOI
  52. Sherman, 2020, 1914MO Randomized phase II study of radiation therapy and paclitaxel with pazopanib or placebo: NRG-RTOG 0912, Ann Oncol, 31, S1085, 10.1016/j.annonc.2020.08.1402 · DOI
  53. Takahashi, 2019, A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer, Future Oncol (London, England), 15, 717, 10.2217/fon-2018-0557 · DOI
  54. Wirth, 2021, Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer, J Clin Oncol, 39, 2359, 10.1200/JCO.20.03093 · DOI
  55. Savvides, 2013, Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid, Thyroid, 23, 600, 10.1089/thy.2012.0103 · DOI
  56. Bible, 2012, A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer, J Clin Endocrinol Metab, 97, 3179, 10.1210/jc.2012-1520 · DOI

Cited by

Sorted by citations

See all 80

Metadata

Authors
Maniakas, A., Zafereo, M., & Cabanillas, M. E.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Cabanillas, Maria E.
ORCID
Venue
Endocrinology and Metabolism Clinics of North America
Publisher
Elsevier BV
Published
2022-06
Volume
51
Issue
2
Pages
391-401
ISSN
0889-8529 (ISSN-L)
DOI
10.1016/j.ecl.2021.11.020
OpenAlex
W4225417120
Cited by
80
References
4
Citations by year
2026: 15 · 2025: 30 · 2024: 19 · 2023: 13 · 2022: 3
FWCI
2.31
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Endocrinology and Metabolism Clinics of North America (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Merck
  • Exelixis
  • Eli Lilly and Company
  • Genentech
  • Eisai
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords
anaplastic thyroid carcinoma, targeted therapy, immunotherapy, cytotoxic chemotherapy, radiotherapy, thyroid surgery, adjuvant therapy, multidisciplinary treatment, personalized medicine, palliative care
MeSH terms
Combined Modality Therapy, Humans, Immunotherapy, Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review